乳腺X线特征在不同Luminal型乳腺癌诊断中的价值

目的探讨乳腺X线特征与不同Luminal型乳腺癌的相关性。方法回顾性分析371例Luminal型乳腺癌的临床病理及乳腺X线特征,根据Luminal型乳腺癌的分型标准,将患者分成Luminal A型和Luminal B型两组。分析两组患者中的临床病理、乳腺X线特征的差异,用二元logistic回归分析Luminal B型乳腺癌的独立影响因素,用受试者工作特征曲线的曲线下面积(AUC)评价其诊断效能。结果371例乳腺癌患者中73例(19.7%)Luminal A型,298例(80.3%)Luminal B型;病理SBR分级高、合并脉管侵犯者多出现在Luminal B型乳腺癌中(P<0.05)。征象类别、腋窝淋巴结肿大在不同Luminal型乳腺癌中的差异有统计学意义(P<0.001);肿块、钙化及肿块合并钙化的病灶多出现在Luminal B型乳腺中(P=0.028、0.034、0.007),结构扭曲的病灶多出现在Luminal A型乳腺癌中(P=0.005)。logistic回归表明病理SBR 2级、SBR 3级、伴钙化及腋窝淋巴结肿大是Luminal B型乳腺癌的独立影响因素(OR=3.912、31.687、2.498、4.210),而结构扭曲征象则是Luminal B型乳腺癌的保护因素(OR=0.155);临床病理特征、乳腺X线征象及两者联合预测Luminal B型乳腺癌的AUC为0.661、0.691和0.758。结论不同Luminal型乳腺癌与乳腺癌的临床病理、X线特征有一定的相关性,有助于Luminal型乳腺癌的分型诊断。

体素内不相干运动定量参数评估浸润性乳腺癌Luminal分型研究

目的探讨体素内不相干运动(intravoxel incoherent motion,IVIM)定量参数鉴别Luminal型与非Luminal型浸润性乳腺癌的价值。方法收集经病理证实为浸润性乳腺癌患者148例,其中Luminal型乳腺癌86例,非Luminal型乳腺癌62例。测量感兴趣区的IVIM参数值[真扩散系数(slow ADC,D)、假扩散系数(fast ADC,D^(*))和灌注分数(perfusion fraction,f)],比较两组间各参数的差异,绘制受试者工作特征(receiver operating characteristic,ROC)曲线评价各参数及两者联合对Luminal型与非Luminal型乳腺癌的鉴别效能。结果Luminal型乳腺癌组的D值[(0.71±0.09)×10^(-3)mm^(2)/s vs(0.84±0.10)×10^(-3)mm^(2)/s]和f值[18.56(16.00,23.94)vs 24.90(21.01,32.98)]均低于非Luminal型组,组间差异具有统计学意义(P均<0.05),而D^(*)值在两组间差异无统计学意义。ROC结果显示联合D及f值的曲线下面积(area under the curve,AUC)、特异性及敏感度分别为0.866、81.4%、79.0%。结论体素内不相干运动定量参数D值和f值可帮助鉴别Luminal型与非Luminal型乳腺癌,两者联合诊断效能更佳。

Identifying microRNA-Target Gene Pairs in Luminal B Breast Cancer Using Integrated Analysis of miRNA and Transcriptome Profiles

Dysregulation of post-transcriptional regulation of gene expression has been found to influence various human disorders. Aberrant miRNA-based regulation of gene expression has been found to be associated with different cancers, including breast cancers. Very little information is available on the effect of dysregulation of miRNA-mediated regulation on luminal B breast cancer. This study was aimed at comprehending the regulation of gene expression through miRNA in luminal B breast cancers by comprehensive analysis of miRNA and mRNA expression data together. Negatively regulated miRNA-target gene pairs were identified, and the target genes were functionally enriched to identify critical pathways associated with luminal B breast cancer. Further, the prognostic significance of these miRNAs and target gene pairs was assessed to identify genes with prognostic value in luminal B breast cancer. A total of 266 differentially expressed miRNAs and 164 dysregulated miRNA-target gene pairs were identified. Four genes, including SRP9, DSN1, RACGAP1, and SLC10A6, and one miRNA, hsa-mir-421, showed significant influence on the prognosis of patients with luminal B breast cancer. Through additional experimental examination of these findings, a deeper comprehension of miRNA-based post-transcriptional regulation in luminal B breast tumors will be possible.

Luminal B型男性乳腺癌1例并文献复习

乳腺癌是女性常见恶性肿瘤,男性相对少见[1]。男性乳腺癌(male breast carcinoma,MBC)在所有乳腺癌患者占比<1%,在男性所有癌症中占比<1%,但发病率呈缓慢上升趋势[2],临床上以中老年患者多见[3]。MBC发病率较低,发现时往往分期较晚,恶性程度较高[4],缺乏特定治疗手段,预后较差[5]。临床上对于MBC的治疗建议通常参考女性乳腺癌的临床试验结果。本文报告1例Luminal B型MBC的诊治,并复习相关文献,为临床诊疗MBC提供参考。

DDHD2 is involved in the malignant progression of early luminal A breast cancer by changing cell membrane proteins and immune responses functionality

Background:Luminal A breast cancer has the best prognosis of all malignant breast cancer types.In clinical practice,some patients with luminal A breast cancer present with small tumors(usually<20 mm)but with lymph node metastases or even distant organ metastasis.Owing to their insensitivity to chemotherapy and the lack of conclusive clinical evidence,there is a significant gap in research on luminal A breast cancer with high invasiveness.This study aimed to identify genes that drive the invasiveness of luminal A breast cancer and explore the underlying mechanisms.Methods:In this study,we first utilized bioinformatics techniques to analyze differentially expressed mRNAs and enrich common functional pathways to identify the target gene DDHD domain containing 2(DDHD2).We then evaluated the association between DDHD2 expression and patient prognosis,genetic material changes,and transcriptional,translational,and immune responses in luminal A breast cancer.We also conducted experiments at the molecular and cellular levels to validate these biochemical mechanisms.Results:The expression of DDHD2 varied between patients with low-grade luminal A breast cancer with and without lymph node metastases.Our findings demonstrated that DDHD2 exerted carcinogenic effects through various pathways by altering cell adhesion and migration,regulating cell proliferation and apoptosis cycles,and suppressing immune responses.Moreover,a pathway through which DDHD2 inhibited immunity was preliminarily verified.Conclusions:The results revealed a novel role for DDHD2 in promoting the malignant transformation and invasiveness of luminal A breast cancer.Considering its effects on the tumor microenvironment and tumor-infiltrating immune cells in the epithelial-mesenchymal transition,DDHD2 is proposed as a reliable direction for future immunotherapy and a potential target in luminal A breast cancer immune resistance.

Luminal型乳腺癌中PD-L1、CD8^(+)T淋巴细胞的表达特点及预测价值

目的 讨论Luminal型乳腺癌中PD-L1、CD8^(+)T淋巴细胞的表达特点及预测价值。方法 收集2022年1月至2023年10月于本院治疗的Luminal型乳腺癌病例共54例。收集患者临床资料(年龄、家族史、合并症等),病理资料(TNM分期、PR%、病理学分级等),使用Cox生存分析判断生存的独立因素。结果 Luminal型乳腺癌患者CD8^(+)T表达在绝经状态、肿瘤分期、Ki-67方面有统计学差异,肿瘤细胞中程序性死亡配体1(programmed death ligand 1,PD-L1)的表达与TNM分期、TIL评分、PR%、Ki-67、分子分型相关,肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TILs)中PD-L1的表达TNM分期、TIL评分、PR%、Ki-67、分子分型、ER%相关,CD8^(+)T表达与肿瘤细胞、TILs中PD-L1的表达有统计学差异,Luminal型乳腺癌患者生存的独立危险因素包括PR%、IC评分、Ki-67和病理学分级。结论 CD8^(+)T淋巴细胞抑制Luminal型乳腺癌的增殖和转移,PD-L1在TILs中的表达、PR%、Ki-67和病理学分级对Luminal型乳腺癌患者的生存预后具有一定的预测价值。

MRI预测乳腺非特殊型浸润性导管癌Luminal分型的临床价值

目的:探讨乳腺非特殊型浸润性导管癌Luminal分型的MRI表现,为乳腺非特殊型浸润性导管癌的诊疗提供更优的选择。方法:回顾性分析2018年10月8日—2021年12月1日经样本医院手术病理证实为乳腺非特殊型浸润性导管癌的119例女性患者的临床及影像学资料。比较Luminal型和非Luminal型的临床特征及MRI影像特征。绘制ROC曲线,计算ROC曲线下的面积及截断点。结果:119例乳腺非特殊型浸润性导管癌中,Luminal型72例,非Luminal型47例。患者有无淋巴结转移、肿瘤的最大径、肿瘤形态、TIC曲线、最小表观扩散系数(apparent diffusion coefficient,ADC)值和平均ADC值比较,差异统计学意义(P<0.05)。当最小ADC值和平均ADC值分别为0.851×10^(-3)mm^(2)/s、0.849×10^(-3)mm^(2)/s时,其特异度和敏感度分别为0.553、0.806和0.681、0.750,ROC曲线下面积分别为0.745、0.761。结论:MRI可以提高乳腺非特殊型浸润性导管癌的诊断效能,其ADC值可作为其临床及预后的重要指标,更有利于临床进行更精准的治疗。

GATA3与FOXA1在luminal亚型乳腺癌细胞中相互作用的研究

目的:探讨GATA3与FOXA1在luminal亚型乳腺癌细胞中的相互作用。方法:基于cBioportal For Cancer Genomics公共数据库中乳腺癌临床病例数据集,分析luminal A、luminal B和basal-like亚型乳腺癌组织中GATA3与FOXA1mRNA表达水平的相关性;利用蛋白-蛋白相互作用数据库STRING和分析工具Cytoscape预测GATA3与FOXA1的相互作用。以luminal亚型的MCF-7和T-47D乳腺癌细胞以及basal-like亚型的MDA-MB-231和SUM-149PT乳腺癌细胞为研究对象,采用RT-qPCR和Western印迹检测GATA3和FOXA1的mRNA和蛋白表达水平;细胞免疫荧光检测GATA3和FOXA1的细胞定位;蛋白质免疫共沉淀验证GATA3与FOXA1之间的相互作用。结果:临床病例数据分析显示GATA3与FOXA1在luminal A、luminal B和basal-like亚型乳腺癌组织中mRNA的表达均呈正相关(r=0.4047、0.4761、0.5876,均P<0.0001)。蛋白质相互作用预测显示GATA3与FOXA1存在潜在的相互作用关系。Luminal乳腺癌细胞中GATA3和FOXA1的mRNA(t=80.95、79.73、33.84、33.60,均P<0.0001;t=15.24、5.21、14.95、14.93,均P<0.001)和蛋白(t=29.63、28.48、36.60、35.60,均P<0.0001;t=34.06、35.30、75.01、74.32,均P<0.0001)表达水平显著高于basal-like细胞。GATA3与FOXA1在MCF-7和T-47D细胞核中共定位。GATA3与FOXA1存在蛋白相互作用。结论:GATA3与FOXA1可能通过相互作用维持luminal亚型乳腺癌表型稳态,抑制肿瘤恶性进展。

LuminalB型乳腺癌原发灶和同侧腋窝淋巴结转移灶中CD147和MMP-2的表达差异及其临床意义

研究细胞外基质金属蛋白酶诱导因子(CD147)和基质金属蛋白酶-2(MMP-2)在luminal B型乳腺癌原发灶和同侧腋窝淋巴结转移灶中的表达差异及其临床意义,探讨CD147及MMP-2在该分型乳腺癌的表达与预后的关系。方法 提取luminal B型的乳腺癌数据,分别对CD147及MMP2进行单基因分析。选取了2013年06月至2018年01月在贵州医科大学附属医院乳腺外科的67名接受手术治疗的女性luminai B型乳腺癌患者。检测其中原发灶与淋巴结转移灶的雌激素受体(ER)、孕酮受体(PR)、人表皮生长因子受体2(HER-2)、Ki-67、CD147和MMP-2的表达。电话随访调查其生存情况。结果 1相关性分析结果表明,MMP-2在淋巴结转移灶中的表达差异与临床分期有关(p<0.05),但与年龄、家族遗传史和肿瘤大小无关(p>0.05);CD147和MMP-2在原发灶和腋窝淋巴结中的表达被分为四个亚组进行分析,CD147和MMP-2的OS(overall survival)总体差异具有统计学意义(p<0.05)。

表观扩散系数术前区分Luminal型与非Luminal型乳腺癌及其与Ki-67增殖指数的相关性研究

目的 探讨表观扩散系数(apparent diffusion coefficient, ADC)术前区分Luminal型与非Luminal型乳腺癌的效能及其与Ki-67增殖指数之间的相关性。材料与方法 回顾性分析经病理证实为Luminal型乳腺癌88例和非Luminal型乳腺癌30例,并检测其Ki-67增殖指数。在ADC图上测量病灶实质的最小ADC值(the minimum ADC, ADCmin)、平均ADC值(the mean ADC, ADCmean)和相应对侧正常乳腺腺体组织的ADC值,计算相对ADCmin (relative ADCmin, rADCmin)和相对ADCmean(relative ADCmean, rADCmean)。比较Luminal型与非Luminal型乳腺癌组间ADC值差异,绘制受试者工作特征(receiver operating characteristic, ROC)曲线,分析ADC值对Luminal型与非Luminal型乳腺癌的鉴别效能及其与Ki-67增殖指数间的相关性。结果 Luminal型乳腺癌组的ADCmin、ADCmean、rADCmin和rADCmean值均低于非Luminal型乳腺癌组,组间差异具有统计学意义(P均<0.05)。ROC结果显示各ADC值均能对Luminal型与非Luminal型乳腺癌进行有效区分,其中,rADCmin鉴别效能最佳,最佳截止值为0.599,相应的曲线下面积(area under the curve, AUC)、敏感度、特异度分别为0.796 [95%(confidence interval, CI):0.712~0.864]、90.91%(95%CI:82.90%~96.00%)和63.33%(95%CI:43.90%~80.10%)。乳腺癌ADCmin、ADCmean、rADCmin和rADCmean与Ki-67增殖指数间均呈不同程度的负相关关系[r=-0.343(95%CI:-0.493~-0.173)、 r=-0.474 (95%CI:-0.603~-0.321)、 r=-0.325 (95%CI:-0.478~-0.154)、 r=-0.322 (95%CI:-0.475~-0.150),P均<0.05]。结论 ADC值可用于鉴别Luminal型与非Luminal型乳腺癌,可以在一定程度上评估肿瘤细胞增殖活性。

ENST00000535926 is an unfavorable prognosis-related and tumorpromoting transcript of the CHPF gene in luminal A and B breast cancer

Chondroitin sulfate synthase 2(CHPF)is characterized as an oncogenic and poor prognosis-related gene in breast cancer.However,this gene has alternative splicing products encoding proteins of different lengths.Breast cancer is a group of heterogeneous tumors with distinct clinical and genomic characteristics.In this study,we explored the expression profile and prognostic value of the two transcripts of CHPF using data from The Cancer Genome Atlas(TCGA)-BRCA.The functional regulation of the two transcripts was also studied in MCF-7 and BT-474 cells.Among the two transcripts of CHPF,ENST00000535926 expression was significantly upregulated in the tumor samples and was the dominant isoform.ENST00000535926,but not ENST00000243776 upregulation,was associated with significantly worse progression-free survival(PFS)and disease-specific survival(DSS)in luminal A/B cases.However,no significant association was observed in PFS or DSS in other Prediction Analysis of Microarray 50(PAM50)subgroups.CHPF isoform 2 protein(encoded by ENST00000535926)significantly elevated the expression of P3H1 and RCN3 at the mRNA and protein levels in MCF-7 and BT-474 cells.The effect of ENST00000535926 was significantly stronger than ENST00000243776 in promoting tumor cell colony formation.The expression of P3H1 and RCN3 was negatively correlated with CD8+T cell infiltration but was positively correlated with cancer-associated fibroblast infiltration in luminal A/B tumors.In summary,this study revealed that ENST00000535926 is an unfavorable prognosis-related and tumor-promoting transcript of the CHPF gene in luminal A/B breast cancer.

Yes相关蛋白1和散乱蛋白2对Luminal型乳腺癌预后的影响

目的研究Yes相关蛋白1(YAP1)和散乱蛋白2(DVL2)在Luminal型乳腺癌组织及癌旁组织中的表达情况,分析其与临床病理特征及预后的关系。方法采用Real-Time PCR和免疫组化方法检测202例Luminal型乳腺癌组织中YAP1、DVL2 mRNA和蛋白表达水平,分析YAP1和DVL2与乳腺癌患者临床病理特征及预后的关系;采用Cox回归分析乳腺癌患者无瘤生存时间的影响因素;Kaplan-Meier生存曲线分析乳腺癌患者YAP1、DVL2表达水平与无瘤生存时间的关系。结果DVL2蛋白的表达水平与乳腺癌患者的TNM分期、有无神经侵犯及癌栓有关。YAP1与腋窝淋巴结、TNM分期、有无神经侵犯及癌栓有关。YAP1 mRNA与DVL2 mRNA表达呈正相关,Cox回归分析结果显示DVL2和YAP1是乳腺癌患者无瘤生存时间的独立影响因素。Kaplan-Meier生存曲线显示DVL2高表达的乳腺癌患者无瘤生存时间较短,而YAP1高表达的乳腺癌患者的无瘤生存时间较长,联合DVL2和YAP1蛋白表达水平分析显示DVL2(-)YAP1(+)组中Luminal型乳腺癌患者的无瘤生存时间明显长于其他3组。结论DVL2和YAP1在Luminal型乳腺癌组织及癌旁正常组织中有不同程度的表达,与乳腺癌患者的某些临床病理特征及无瘤生存时间有关,二者在乳腺癌组织中的表达水平有相关性。

超声造影定量参数对Luminal型乳腺癌诊断价值及其与雄激素受体及Ki-67的相关性研究

目的:探讨超声造影定量参数在Luminal型乳腺癌诊断中的价值,分析Luminal型乳腺癌患者超声造影定量参数与其雄激素受体(AR)及肿瘤增殖细胞相关抗原Ki-67的相关性。方法:选取医院收治的90例Luminal型乳腺癌患者,并根据病理及免疫组化检测结果将其分为LuminalA型组(32例)和LuminalB型组(58例),比较两组患者超声造影表现差异及定量参数,同时比较定量参数与Ki-67及AR表达水平的相关性。结果:两组患者的超声造影增强强度、灌注缺损、增强边界及穿入血流表现比较,差异均有统计学意义(x^(2)=5.204,x^(2)=11.880,x^(2)=6.556,x^(2)=7.249;P<0.05)。LuminalB型组患者与LuminalA型组相比,病灶区域血流灌注的峰值强度(PI)上升,达峰时间(TTP)及平均渡越时间(TOF)下降,差异均有统计学意义(t=8.084,t=8.639,t=7.945;P<0.05)。LuminalA型组患者Ki-67及AR阳性检出率低于LuminalB型组,差异有统计学意义(x^(2)=4.224,x^(2)=4.262;P<0.05)。90例Luminal型乳腺癌患者PI与Ki-67和AR表达水平均呈正相关(r=0.159,r=0.657;P<0.05);TTP、TOF与Ki-67和AR表达水平均呈负相关(r=-0.537,r=-0.407;r=-0.503,r=-0.023;P<0.05)。结论:超声造影定量参数对Luminal型乳腺癌的临床诊断价值较高,并与AR、Ki-67具有一定的相关性,可用于对Luminal型乳腺癌状况变化的诊断评估。

Luminal A型乳腺癌临床病理学及超声特征与腋窝淋巴结转移的关联分析

目的:探讨Luminal A型乳腺癌临床病理学及超声特征与腋窝淋巴结转移的关系。方法:研究对象为2016年1月—2022年10月南京医科大学第一附属医院收治的301例Luminal A型乳腺癌女性患者,其中82例为淋巴结转移组,219例为未转移组。采用单因素及多因素logistic回归分析患者临床病理学资料、肿块及腋窝淋巴结超声图像特征与腋窝淋巴结转移的相关性。结果:单因素分析结果显示,超声图像中肿块大小、形态、边缘及腋窝淋巴结超声图像中短径、长径/短径(L/S<2)、淋巴门结构消失、皮质厚度(>3 mm)、血供类型(非淋巴门型)及血流(丰富)差异有统计学意义,与淋巴结转移具有相关性(P<0.05);多因素logistic回归分析,超声图像中的肿块大小(OR=1.842,P=0.016)、淋巴结皮质厚度(OR=2.649,P=0.036)、L/S(OR=0.354,P=0.007)及淋巴结血流(OR=2.255,P=0.039)是Luminal A型乳腺癌腋窝淋巴结转移的独立影响因素。结论:Luminal A型乳腺癌患者临床病理学及超声特征可以预测腋窝淋巴结转移,为临床医师针对Luminal A型乳腺癌的治疗提供参考。

Endoscopic luminal stenting:Current applications and future perspectives

Endoscopic luminal stenting(ELS)represents a minimally invasive option for the management of malignant obstruction along the gastrointestinal tract.Previous studies have shown that ELS can provide rapid relief of symptoms related to esophageal,gastric,small intestinal,colorectal,biliary,and pancreatic neoplastic strictures without compromising cancer patients’overall safety.As a result,in both palliative and neoadjuvant settings,ELS has largely surpassed radiotherapy and surgery as a first-line treatment modality.Following the abovementioned success,the indications for ELS have gradually expanded.To date,ELS is widely used in clinical practice by well-trained endoscopists in managing a wide variety of diseases and complications,such as relieving non-neoplastic obstructions,sealing iatrogenic and non-iatrogenic perforations,closing fistulae and treating post-sphincterotomy bleeding.The abovementioned development would not have been achieved without corresponding advances and innovations in stent technology.However,the technological landscape changes rapidly,making clinicians’adaptation to new technologies a real challenge.In our mini-review article,by systematically reviewing the relevant literature,we discuss current developments in ELS with regard to stent design,accessories,techniques,and applications,expanding the research basis that was set by previous studies and highlighting areas that need to be further investigated.

基于T2WI、DCE磁共振影像组学对Luminal型乳腺癌分子分型的预测价值研究

目的:探讨基于T_(2)WI、DCE磁共振影像组学模型对Luminal型乳腺癌分子分型的预测价值。方法:回顾性收集2018年1月—2021年10月昆明医科大学第一附属医院经病理证实的140例Luminal型乳腺癌,其中Luminal A型85例、Luminal B(HER-2阴性)型55例,病例按照7:3比例随机分为训练集和测试集。分别在T_(2)WI、DCE图像逐层勾画全病灶感兴趣区并提取影像组学特征。采用t检验和最小绝对缩减和变量选择算子(least absolute shrinkage and selection operator,LASSO)对影像组学特征降维并建立组学标签,通过逻辑回归分别对两个序列影像组学特征建模、训练并验证。应用受试者工作特征(receiver operating characteristic,ROC)曲线评价模型效能,用曲线下面积(area under the curve,AUC)、灵敏度、特异度、准确度表示。结果:T_(2)WI模型训练集AUC为0.94,灵敏度、特异度、准确度为0.83、0.87、0.85,测试集AUC为0.88,灵敏度、特异度、准确度为0.77、0.94、0.83;DCE模型训练集AUC为0.63,灵敏度、特异度、准确度为0.85、0.26、0.61,测试集AUC为0.65,灵敏度、特异度、准确度为0.88、0.25、0.64。结论:基于T_(2)WI影像组学模型对LuminalA型、Luminal B(HER-2阴性)型乳腺癌分子分型的预测具有良好的效能,预测能力优于DCE影像组学模型。

外周血淋巴细胞亚型在Luminal型乳腺癌中的诊断价值研究

目的探讨外周血淋巴细胞亚群在Luminal型乳腺癌中的诊断价值。方法对纳入研究的83例女性Luminal型乳腺癌患者和102例乳腺良性疾病患者,采集新鲜血,然后通过Cytomics FC500流式细胞仪(Beckman-Coulter)检测外周血淋巴细胞,并通过多色流式细胞仪进行聚类。通过受试者操作曲线评估淋巴细胞亚型在Luminal型乳腺癌中的诊断性能。结果与乳腺良性疾病(102例)相比,Luminal乳腺癌(83例)CD19^(+)淋巴细胞亚型数显着升高(P=0.03),而CD8^(+)CD28^(+)(P<0.05)和DC2(P<0.05)Luminal乳腺癌淋巴细胞亚型显着降低。CD19^(+)^(+)CD8^(+)CD28^(+)^(+)DC2淋巴细胞亚型组合诊断的AUC最高,为0.761(95%CI 0.690,0.832,P<0.01)。结论CD19^(+)、CD8^(+)CD28^(+)和DC2联合可能有助于提高Luminal型乳腺癌的诊断。

晚期Luminal型乳腺癌孕激素受体表达状况与其化疗疗效相关性研究

目的探讨晚期Luminal型乳腺癌孕激素受体(PR)表达与化疗疗效的相关性。方法选取行一线化疗的68例女性晚期Luminal型乳腺癌患者,依据PR阳性率的高低分为PR低表达组(n=35,阳性率<20%)与PR高表达组(n=33,阳性率≥20%)。全部患者均采用吉西他滨+顺铂(GP)方案化疗,21 d为1个周期,共化疗4个周期。于化疗结束后评估疗效,同时随访3年,分析PR高、低表达与晚期Luminal型乳腺癌患者生存周期的关系。结果PR高表达组的治疗总有效率[93.94%(31/33)]高于PR低表达组[74.29%(26/35)],有统计学差异(P<0.05);Kaplan-Meier结果显示:PR高表达组的3年生存率高于PR低表达组,有统计学差异(P<0.05)。结论晚期Luminal型乳腺癌患者PR表达状况与化疗疗效相关,在PR低表达的晚期Luminal型乳腺癌患者中采取GP化疗方案治疗效果较差,且生存率更低,临床需予以高度的重视,及时测定PR表达水平,据此采取针对性治疗,以增强治疗效果,尽可能改善患者预后。

Cultural and luminescent Conditions of a Marine luminous Bacterium

Study of marine noctilucence in marine is important to fishery, environmental monitoring and military affairs. A luminous bacterial strain D2 was isolated from the marine sediment samples collected near Donghai Island in Zhanjiang, China. The primary cultural and luminescent conditions of luminous bacterium D2 which was identified as Vibrio sp. were determined in liquid culture. The results showed that pH 7.0, 35 ℃, with 2.0 % NaCI, were the best growth conditions, and pH5 - 6, 20℃, OD600 0.08, with 3.0 % NaCI, were the optimal luminescent conditions.

药物去势联合化疗在绝经前Luminal A型乳腺癌新辅助化疗中的疗效及安全性评价

背景与目的:常规新辅助化疗方案在治疗Luminal A型乳腺癌患者中达病理完全缓解(pathologic complete remission,pCR)率小于10%,寻求新型的新辅助化疗方案以提高pCR率从而进一步改善患者的预后具有重要的临床意义。我们对卡培他滨联合多西他赛(XT方案)加或不加戈舍瑞林去势在中国人群绝经前Luminal A型乳腺癌新辅助化疗的疗效及安全性方面进行了初步评价。方法:纳入研究的36例患者被随机分配至XT组或XT+去势组。两组患者术前均接受4周期XT方案新辅助化疗,XT+去势组同时接受新辅助戈舍瑞林去势治疗。主要终点为pCR率,次要终点为总体反应(overall response,OR)率。并按CTCAE v3.0对不良反应事件进行分级。采用四格表检验比较组间的pCR率与OR率的差异。结果:总共纳入36例符合入组标准的患者,按1:1随机至XT组与XT+去势组,两组患者平均年龄分别为40.6岁(27～48岁)与42.8岁(27～48岁)。所有患者均按计划完成术前4个周期新辅助治疗。XT组pCR率为16.7%,OR率为94.4%。XT+去势组pCR率为16.7%,OR率为100%。两组的pCR率与OR率均无显著差异。两组患者在新辅助化疗过程期间均未发现需要调整剂量的严重不良反应事件。结论:新辅助XT±戈舍瑞林去势在中国人群绝经前Luminal A型乳腺癌中有较高的pCR率及OR率,同时具有较高的安全性。